Luminoimmunometric assay of tissue polypeptide antigen (TPA) and cancer antigen 125 (CA-125) in breast cancer patients.
Serum TPA and CA-125 were determined in 86 individuals (66 with breast cancer representing the different stages and grades of the disease and 20 normal healthy controls). TPA and CA-125 were estimated using the LIA reagents supplied by BYK Sangtec. TPA showed sensitivity rates of 31.8%, 42.4% and 51.5% while CA-125 showed sensitivities of 16.3%, 18.6% and 25.6% at specificity levels of 100%, 95% and 90% respectively. Combined determination of the two markers resulted in some improvement in sensitivity. For follow-up of breast cancer patients after surgery both markers were of value and showed near-identical patterns.
el-Ahmady
O
O
Tumor Marker Oncology Research Unit, Al-Azhar University, Cairo, Egypt.
Halim
A B
AB
Eissa
S
S
D000328:Adult; D000368:Aged; D015295:Antigens, Tumor-Associated, Carbohydrate / Q000097:blood*; D001943:Breast Neoplasms / Q000097:blood*; D005260:Female; D006801:Humans; D007118:Immunoassay; D008163:Luminescent Measurements; D008875:Middle Aged; D009367:Neoplasm Staging; D010455:Peptides / Q000097:blood*; D019396:Tissue Polypeptide Antigen
D015295:Antigens, Tumor-Associated, Carbohydrate; D010455:Peptides; D019396:Tissue Polypeptide Antigen